Related Experiment Video

Updated: May 16, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer

Jonathan W Riess1, Joel W Neal

  • 1Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California 94305, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|November 20, 2012
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 16, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Articles linked to this work by shared authors, journal, and citation graph.

Metabolomic and lipidomic profiling reveals distinct subtypes of glioblastoma IDH-wildtype and shared metabolic features with astrocytoma IDH-mutant grade 4.

Neuro-oncology advances·2026

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology·2026

Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.

Non-coding RNA·2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

The Lancet. Respiratory medicine·2026

Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.

JCO oncology practice·2026

Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association between ASXL1 and Lung Cancer Risk.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Integrated multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant lung adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us